FDA Approves First Targeted RAS Drug for Metastatic Pancreatic Cancer

The FDA approved Revolution’s Rasonque, the first RAS-targeted daily pill for metastatic pancreatic cancer. It doubled median survival to 13.2 months, compared with 6.7 months with chemotherapy.